Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Ex
Patients diagnosed with prostate cancer and receiving hormone therapy in conjunction with radiotherapy are likely to suffer from adverse effects caused by ADT treatment either short term or long term. The most common side effects include changes in body composition leading to increased visceral fat and reduced lean mus
| Condition(s) | Prostate Cancer, Prostate Cancer (Diagnosis) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Patients diagnosed with prostate cancer and receiving hormone therapy in conjunction with radiotherapy are likely to suffer from adverse effects caused by ADT treatment either short term or long term. The most common side effects include changes in body composition leading to increased visceral fat and reduced lean muscle mass, increased risk of cardiovascular events and fatigue, which overall lower quality of life. There is strong evidence to support exercise interventions in minimising, and in some cases reversing many ADT -related toxicities, but exercise adherence remains a challenge for people living with prostate cancer, particularly due to logistical barriers to attendance such as cost and travel time, as well as insufficient motivation. The aim of this single centre, phase III rand |
| Who can participate | Inclusion Criteria: 1. Age \> 18 at randomisation 2. Men with histological confirmation of prostate adenocarcinoma who are receiving or planned to receive ADT with an LHRHa as part of their PCa treatment 3. If already started ADT, have received no more than eight weeks ADT at randomisation 4. Planned for radiotherapy 5. Assessed by clinical team to be safe to exercise and safe to enter the trial with no absolute contraindications to exercise as defined by clinical guidance 6. Able to use technological aspects of the intervention including access to MyMarsden and a device for video conferencing 7. Fluent in English and able to understand instructions 8. WHO performance status 0-2 9. Able to give written informed consent Exclusion Criteria: 1. Men planned to receive an androgen receptor-targ |
| Ages | 18 Years |
| Sex | Male |
| Lead sponsor | Royal Marsden NHS Foundation Trust |
| Locations | London, United Kingdom |
| Start date | 2025-12-16 |
| NCT ID | NCT07243834 |
| Official listing | https://clinicaltrials.gov/study/NCT07243834 |